Brief: Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction In Pain
23/01/2019 13:34
Jan 23 (Reuters) - XBiotech Inc XBIT.O :
* BERMEKIMAB SUCCESSFULLY TREATS HIDRADENITIS SUPPURATIVA,
INCLUDING SIGNIFICANT REDUCTION IN PAIN
* XBIOTECH INC - PRIMARY AND KEY SECONDARY ENDPOINTS WERE
MET IN
THIS STUDY
* XBIOTECH INC - BERMEKIMAB WAS WELL-TOLERATED WITH NO
SAFETY
CONCERNS
Source text for Eikon: ID:nGNEQjLCT
Further company coverage: XBIT.O
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke